NOT KNOWN FACTS ABOUT HOW TO USE MOUNJARO

The trial achieved both its Main endpoints, with semaglutide two.four mg demonstrating statistically important and outstanding improvements in liver fibrosis without having worsening of steatohepatitis, and also resolution of steatohepatitis without having worsening of liver fibrosis in individuals with MASH in comparison with placebo.1The followin